The authors precisely note the lack of randomized managed trials for orthopaedic indications—this means we can’t confidently say it works, what the actual facet-outcome profile is, or what a “safe dose” would be in the actual environment (systematic evaluation, 2024).In case the intention is “significantly less downtime, additional traini… Read More